IMMX
MaterialsImmix Biopharma Inc
$10.32+0.76 (+7.95%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving IMMX Today?
No stock-specific AI insight has been generated for IMMX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$547M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding53.0M
IMMX News
20 articles- Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?Yahoo Finance·May 5, 2026
- We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business GrowthYahoo Finance·May 5, 2026
- Immix Biopharma to Participate in the Jefferies Global Healthcare ConferenceYahoo Finance·Apr 9, 2026
- Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming MilestonesYahoo Finance·Mar 30, 2026
- Immix Biopharma to Participate in Upcoming Investor ConferencesYahoo Finance·Mar 3, 2026
- Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX)Yahoo Finance·Feb 13, 2026
- Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201Yahoo Finance·Jan 28, 2026
- Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Dec 9, 2025
- Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsYahoo Finance·Dec 7, 2025
- At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL AmyloidosisYahoo Finance·Dec 7, 2025
- We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth CarefullyYahoo Finance·Nov 24, 2025
- Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 LaunchYahoo Finance·Nov 12, 2025
- Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025Yahoo Finance·Nov 3, 2025
- Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insidersYahoo Finance·Oct 28, 2025
- Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation ConferenceYahoo Finance·Oct 14, 2025
- Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual MeetingYahoo Finance·Oct 6, 2025
- Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare ConferenceYahoo Finance·Oct 1, 2025
- Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2Yahoo Finance·Sep 18, 2025
- Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of DirectorsYahoo Finance·Sep 11, 2025
- Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. ChangYahoo Finance·Sep 8, 2025
All 20 articles loaded
Price Data
Open$9.50
Previous Close$9.56
Day High$9.94
Day Low$8.82
52 Week High—
52 Week Low—
Fundamentals
Market Cap$547M
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding53.0M
About Immix Biopharma Inc
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—